Larimar Therapeutics appoints Dr. Jeffrey W. Sherman to Board of Directors

Larimar Therapeutics, Inc.

Board expanded from 5 to 6 members; Dr. Sherman appointed as Class I director through 2024 annual meeting.
Dr. Sherman is EVP and Chief Medical Officer of Horizon Therapeutics, with extensive biopharma leadership experience.
Received option to purchase 16,600 shares of common stock, vesting monthly over 36 months.
Appointed to Nominating and Corporate Governance Committee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeffrey W. Sherman

Class I Director

LRMR · Larimar Therapeutics, Inc.

Effective: 2023-10-03
Filed: October 3, 2023, 7:59 PM ET

On October 3, 2023 (the “ Appointment Date ”), the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”) increased the size of the Board from five to six members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Jeffrey W. Sherman, MD, FACP to serve as a Class I director, with an initial term expiring at the Company’s 2024 Annual Meeting of Stockholders, and a member of the Nominating and Corporate Governance Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jeffrey W. Sherman was appointed as Class I Director at Larimar Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On October 3, 2023 (the “ Appointment Date ”), the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”) increased the size of the Board from five to six members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Jeffrey W. Sherman, MD, FACP to serve as a Class I director, with an initial term expiring at the Company’s 2024 Annual Meeting of Stockholders, and a member of the Nominating and Corporate Governance Committee.

View on SEC.gov

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-249962

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.